60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results

• Q3 2025 net product revenue increased 223% year-over-year to $438 thousand
• Gross profit/(loss) decreased from $24 thousand to $(100) thousand

WASHINGTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, reported today its financial results for the third fiscal quarter of the 2025 year, ended September 30, 2025.

Financial Highlights for the Quarter Ended September 30, 2025:

• ARAKODA pharmacy deliveries increased by 14% from 1,319 boxes (Q3 2024) to 1,505 boxes (Q3 2025).
• The Company posted a gross loss of approximately $100 thousand in the third quarter of 2025, compared to an approximate gross profit of $24 thousand in the third quarter of 2024, due to a one-time inventory write-off associated with newly produced validation lots which will no longer be accepted by supply chain partners after the end of Q1 2026 due to limited remaining shelf-life. Additional lots with four-year shelf-life are currently in production and expected to fully enter the supply chain in early Q1 2026.
• Operating expenses were approximately $2.32 million in the third quarter of 2025, compared to approximately $2.16 million in the third quarter of 2024. The increase in expenses is primarily driven by the $367 thousand in additional advertising and sales promotion expenditures.
• Net loss attributable to common shareholders in the third quarter of 2025 was approximately $2.44 million, or ($0.66) per share, compared to approximately $2.27 million, or ($4.65) per share in the third quarter of 2024, representing an additional $171K in losses.

Business Highlights for the Quarter Ended September 30, 2025:

• On July 14, 2025, we announced our intention to seek a Minor Use Minor Species (MUMS) designation from the United States Food and Drug Administration (FDA) for the treatment of acute canine babesiosis following a comprehensive gap analysis of our existing data.
• After completing a 6,000 patient nationwide survey and quantitative research study, we announced on July 15, 2025 that we had determined the total addressable market (TAM) for Babesiosis treatment to be up to $1.1 billion through patent expiration in 2035.
• On July 17, 2025, we announced our entry into a sponsored research agreement with Tulane University to evaluate activity of tafenoquine against Borrelia (Lyme) and Bartonella bacteria.
• On August 19, 2025, we announced our partnership with the Icahn School of Medicine at Mount Sinai for our planned Phase II clinical study of tafenoquine in treating chronic babesiosis.

About 60 Degrees Pharmaceuticals, Inc.